View Item 

Show simple item record

Impact of the timing of hepatitis B virus identification and antiâ hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy

dc.contributor.authorHwang, Jessica P.
dc.contributor.authorSuarez‐almazor, Maria E.
dc.contributor.authorCantor, Scott B.
dc.contributor.authorBarbo, Andrea
dc.contributor.authorLin, Heather Y.
dc.contributor.authorAhmed, Sairah
dc.contributor.authorChavez‐macgregor, Mariana
dc.contributor.authorDonato‐santana, Christian
dc.contributor.authorEng, Cathy
dc.contributor.authorFerrajoli, Alessandra
dc.contributor.authorFisch, Michael J.
dc.contributor.authorMcLaughlin, Peter
dc.contributor.authorSimon, George R.
dc.contributor.authorRondon, Gabriela
dc.contributor.authorShpall, Elizabeth J.
dc.contributor.authorLok, Anna S.
dc.date.accessioned2017-10-05T18:16:22Z
dc.date.available2018-12-03T15:34:02Zen
dc.date.issued2017-09-01
dc.identifier.citationHwang, Jessica P.; Suarez‐almazor, Maria E. ; Cantor, Scott B.; Barbo, Andrea; Lin, Heather Y.; Ahmed, Sairah; Chavez‐macgregor, Mariana ; Donato‐santana, Christian ; Eng, Cathy; Ferrajoli, Alessandra; Fisch, Michael J.; McLaughlin, Peter; Simon, George R.; Rondon, Gabriela; Shpall, Elizabeth J.; Lok, Anna S. (2017). "Impact of the timing of hepatitis B virus identification and antiâ hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy." Cancer 123(17): 3367-3376.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/138209
dc.publisherWiley Periodicals, Inc.
dc.subject.otherantiviral therapy
dc.subject.othercancer
dc.subject.otherhematologic malignancies
dc.subject.otherhepatitis B
dc.subject.otherhepatitis B reactivation
dc.subject.otherhepatitis B screening
dc.subject.otherhepatitis flare
dc.subject.otherliver failure
dc.titleImpact of the timing of hepatitis B virus identification and antiâ hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138209/1/cncr30729_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138209/2/cncr30729.pdf
dc.identifier.doi10.1002/cncr.30729
dc.identifier.sourceCancer
dc.identifier.citedreferenceHwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012; 8: e32 â e39.
dc.identifier.citedreferenceLoomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148: 519 â 528.
dc.identifier.citedreferenceWeinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008; 57: 1 â 20.
dc.identifier.citedreferenceReddy KR, Beavers KL, Hammond SP, Lim JK, Falckâ Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015; 148: 215 â 219.
dc.identifier.citedreferenceBaden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancerâ related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14: 882 â 913.
dc.identifier.citedreferenceHwang JP, Somerfield MR, Alstonâ Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015; 33: 2212 â 2220.
dc.identifier.citedreferenceWorld Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. http://apps.who.int/iris/handle/10665/154590. Accessed April 16, 2015.
dc.identifier.citedreferencePark JJ, Wong DK, Wahed AS, et al. Hepatitis B virusâ specific and global Tâ cell dysfunction in chronic hepatitis B. Gastroenterology. 2016; 150: 684 â 695.e5.
dc.identifier.citedreferenceHwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014; 11: 209 â 219.
dc.identifier.citedreferenceSanagawa A, Kuroda J, Shiota A, et al. Outcomes of the implementation of the computerâ assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis. J Pharm Health Care Sci. 2015; 1: 29.
dc.identifier.citedreferenceHsu PI, Lai KH, Cheng JS, et al. Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area. Hepatology. 2015; 62: 387 â 396.
dc.identifier.citedreferenceLau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125: 1742 â 1749.
dc.identifier.citedreferenceLing WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013; 108: 1931 â 1935.
dc.identifier.citedreferenceFine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496 â 509.
dc.identifier.citedreferenceLok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100: 182 â 188.
dc.identifier.citedreferenceHwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarezâ Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013; 13: 534.
dc.identifier.citedreferencePaul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and metaâ analysis. Ann Intern Med. 2016; 164: 30 â 40.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30729_am.pdf
Size:
482.8KB
Format:
PDF
View/Open
Name:
cncr30729.pdf
Size:
296.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.